Estimated disease-free survival according to treatment arms.

(·····) MOPP/ABV, 8 cycles (patients at risk, n = 84; relapse or death, n = 15; 5-year estimate, 80%); () ABVPP, 8 cycles (patients at risk, n = 115; relapse or death, n = 31; 5-year estimate, 68%); (—·—·) MOPP/ABV, 6 cycles plus RTx (patients at risk, n = 108; relapse or death, n = 11; 5-year estimate, 82%); (———) ABVPP, 6 cycles plus RTx (patients at risk, n = 7; relapse or death, n = 18; 5-year estimate, 75%).P = .01.